Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Geelen, J. M.
Right arrow Articles by Levtchenko, E. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Geelen, J. M.
Right arrow Articles by Levtchenko, E. N.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 1766-1770
© 2002 European Renal Association-European Dialysis and Transplant Association

Follow-up and treatment of adults with cystinosis in the Netherlands

Joyce M. Geelen, Leo A. H. Monnens and Elena N. Levtchenko

UMC St Radboud, Department of Pediatric Nephrology, Nijmegen, The Netherlands

Background. Cystinosis is a rare autosomal recessive disease, caused by intracellular cystine accumulation due to a defect in the lysosomal cystine carrier. Treatment with cysteamine favours the transport of cystine out of the lysosomes, diminishes organ damage, and postpones the progression of renal failure. The extra-renal deposition of cystine continues after renal transplantation, leading to later complications. The objective of this study was to evaluate the follow-up, the occurrence of late complications, the social status, and the adequacy of cysteamine treatment in adult patients with cystinosis.

Methods. The medical histories of 10 adult cystinosis patients aged 19–36 years were studied. The impairment of thyroid function, central nervous system, endocrine pancreas, and ocular manifestations, as well as treatment with cysteamine were evaluated.

Results. Eight patients received in total 12 renal grafts, one patient was dialysed and one received conservative treatment for chronic renal failure. Extra-renal complications were noted in six patients, loss of visual acuity in four, hypothyroidism in three, diabetes mellitus in one, cerebral atrophy and epilepsy in one, and swallowing difficulties in two patients. Ophthalmic control was not performed in two patients, thyroid function was not controlled in two and glycaemia not controlled in two patients. Seven patients received 2100–4000 mg cysteamine per day in 2 (n=2), 3 (n=1), 4 (n=3), or 6 (n=1) doses. Cystine concentration in leukocytes was measured once or twice a year in eight patients and was within the recommended range only in three patients.

Conclusion. A high rate of extra-renal complications in adults with nephropathic cystinosis was found. Optimizing the cysteamine therapy may attenuate these complications. Better communication between paediatric and ‘adult's’ nephrologists is needed to improve follow-up and treatment of grown-up cystinosis patients.

Keywords: adults; autosomal recessive; cysteamine treatment; cystinosis; extra-renal involvement

Correspondence and offprint requests to: E. N. Levtchenko, UMC St Radboud, Department of Pediatric Nephrology, P.O. 9101, 6500 HB Nijmegen, The Netherlands. Email: e.levtchenko{at}ckskg.azn.nl


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
CMAJHome page
G. Knoll, S. Cockfield, T. Blydt-Hansen, D. Baran, B. Kiberd, D. Landsberg, D. Rush, E. Cole, and for The Kidney Transplant Working Group of the Can
Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation
Can. Med. Assoc. J., November 8, 2005; 173(10): S1 - S25.
[Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.